On 5 November 2024, Acadia Pharmaceuticals Inc. ("Acadia") announced that it sold its rare paediatric disease priority review voucher...

Vertex Pharmaceuticals announced a reimbursement agreement with NHS England for individuals 12 years or older with transfusion-dependent...

Originally recorded and released in March 2023, this episode of The Roadmap sees Anneke Pol and Toby Crick discuss open source software...

Uses of AI systems in an employment context are to be tightly regulated by the AI Act given the potentially significant impact their use...

Intellectual property is one of the main issues for everyone involved in the burgeoning AI ecosystem. The large generative AI model...

An AI system is classified as “high-risk”, the AI Act imposes significant requirements on the provider in order for it to place the...

What feels really British but isn’t? “Almost everything in the British Museum” goes the old gag. Could a similar analogy be made about...

If your AI system might be “high-risk” under the AI Act, the next question to ask is what role(s) and associated responsibilities does my...

The EU AI Act is a game-changing AI regulatory framework that will be significant for organisations inside and outside the AI industry....

This article was first published in Kluwer Patent Blog [July, 2024]. The recent rivaroxaban PI cases may have caused you to ask yourself...